The results of the TRITON3 study show that patients with prostate cancer treated with a PARP inhibitor, called Rucaparib, take almost twice as long for the disease to progress than those treated with conventional chemotherapy.
The Govern approved today the awarding of the Josep Trueta medals and plaques to outstanding professionals and entities in the health field. Among the award-winning entities is the Bellvitge University Hospital, for its work as a reference center of maximum complexity for 2 million people. Likewise, one of the individual medals has been for Dr. Mònica Povedano, a neurologist at Hospital de Bellvitge and IDIBELL researcher.
The Govern awards the Josep Trueta plaque for health merit to the Hospital de Bellvitge Read More »
The availability and ease of resources, and the time between the appearance of the primary tumor and the start of treatment are key to the patient’s prognosis, already poor in this disease.
A study led by researchers from the Nutrition and Cancer research group of the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) examined the relationship between dietary patterns before breast cancer diagnosis and the survival of these patients.
With the Barradas auditorium full, the 6th IDIBELL sLHam of female scientists was a total success. This year the sLHameres were Sandra Acosta, Begoña Arán, Lidia Franco, Núria Lloberas, Patricia Prada and Gemma Via, Fatima Akhtar and Paula Barrios, who, in a five-minute informative talk, explained their career in the scientific world, the challenges they have been overcoming and the motivations that have helped them to do so.
Great success of the 6th sLHam of women scientists Read More »
A study led by the Bellvitge Biomedical Research Institute (IDIBELL) and the Bellvitge University Hospital (HUB) has discovered an encephalocele in the right temporal pole of the brain in some of patients.
Dra. M Carolina Florian, group leader at IDIBELL, has been appointed as an ICREA Research Professor. ICREA, the Catalan Institution for Research and Advanced Studies, offers permanent, tenured positions to the most talented and extraordinary scientists and academics to come and work in Catalonia. Over the years these positions have become a synonym for global academic excellence.
M Carolina Florian new ICREA Research Professor Read More »
Two researchers from IDIBELL will lead two multicenter research projects on precision personalized medicine: The PRECISION-ILD project lead by Dr Maria Molina (IDIBELL and Bellvitge University Hospital) and IMPaCT_VUSCan project, led by Dr Conxi Lázaro (IDIBELL and Catalan Oncology Institute). Both projects will last for three years, are financed by the Next Generation EU funds and have bee assigned by the Health Institute Carlos III (ISCIII) in a specific call on personalized medicine.
Two IDIBELL teams are granted two research projects on personalized medicine Read More »
The event will be in the Barradas Auditorium in L’Hospitalet de Llobregat on Friday, February 10, at 7 p.m. The 6th sLHam incorporates a novelty: Together with six woman scientists from IDIBELL, two junior sLHamers from the Bellvitge Institute will participate.
According to the results, brentuximab vedotin is effective and safe for some rare types of cutaneous T-cell lymphomas (LCCT)
